Pierre Fabre SA

9 articles about Pierre Fabre SA

• Pierre Fabre Laboratories to accelerate their development in onco-hematology by acquiring the license for a breakthrough T-cell immunotherapy in North America

  11/3/2023

  Pierre Fabre Laboratories announced an expanded global partnership with Atara Biotherapeutics, a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform, for EBVALLO® a monotherapy already registered in the EU for the treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein–Barr virus positive post–transplant lymphoproliferative disease who have received at least one prior therapy.

• 

  Global Roundup: Clover's COVID-19 Vaccine Booster Reaches Phase III

  6/16/2022

  Clover dosed the first participants in a Phase III study of its COVID-19 booster shot, while Global Access Diagnostics, Orbit Discovery, Proximie and more provide business and pipeline updates.

• Pierre Fabre and Lonza Enter Manufacturing Agreement for W0180 Antibody Drug Product

  6/15/2022

  Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, and French pharmaceutical group Pierre Fabre announced that the companies have entered into a manufacturing agreement.

• 

  Global Roundup: Galapagos NV Wins European Approval for Ulcerative Colitis Therapy

  11/18/2021

  Biopharma and life sciences companies from across the globe provide updates. Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
• 

  BioSpace Movers & Shakers, July 16

  7/16/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries

  12/2/2019

  Puma Biotechnology, Inc., a biopharmaceutical company, and Pierre Fabre have agreed to extend the terms of the license agreement in which Puma granted Pierre Fabre exclusive rights to develop and commercialize NERLYNX® within Europe and part of Africa.

• 

  ASCO 2018: Results Keep Rolling In

  6/4/2018

  There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories.

• IQVIA and Pierre Fabre Pharmaceuticals Expand Relationship to Deploy IQVIA’s Orchestrated Customer Engagement

  12/13/2017

  Under the terms of this seven-year agreement, Pierre Fabre Pharmaceuticals will migrate all of its current CRM users to OCE, which Pierre Fabre Pharmaceuticals selected because of its strong “platform of platforms” foundation and open architecture.

• Olivier Bohuon Appointed Chief Executive Officer of Pierre Fabre SA

  9/1/2010